Diffusion Pharmaceuticals, Inc. (DFFN)
Stock Price:
$1.15 USD
0.01 (0.88%)
Updated Aug 5, 2020 9:55 AM EDT - Market open
Key Info
| Market Cap |
68.14M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-11.61M |
| Shares Out |
59.63M |
| EPS (ttm) |
-0.80 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 5, 2020 |
| Last Price |
$1.15 |
| Previous Close |
$1.14 |
| Change ($) |
0.01 |
| Change (%) |
0.88% |
| Day's Open |
1.13 |
| Day's Range |
1.13 - 1.18 |
| Day's Volume |
341,200 |
| 52-Week Range |
0.21 - 2.42 |
More Stats
| Market Cap |
68.14M |
| Enterprise Value |
57.53M |
| Earnings Date (est) |
Aug 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
59.63M |
| Float |
45.86M |
| EPS (basic) |
-1.05 |
| EPS (diluted) |
-0.80 |
| FCF / Share |
-0.31 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
461,652 |
| Short Ratio |
0.24 |
| Short % of Float |
0.93% |
| Beta |
2.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.96 |
| Revenue |
n/a |
| Operating Income |
-11.59M |
| Net Income |
-11.61M |
| Free Cash Flow |
-10.71M |
| Net Cash |
10.60M |
| Net Cash / Share |
0.18 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-39.10% |
| ROE |
-75.25% |
| ROIC |
-2,335.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
3.50
Current: $1.15
High
3.50
Target: 3.50
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | - | - | - | - | 0.37 | 0.57 | 0.04 |
| Revenue Growth | - | - | - | - | - | - | - | -34.35% | 1319.48% | - |
| Gross Profit | - | - | - | - | - | - | - | 0.14 | -1.74 | -0.17 |
| Operating Income | -11.55 | -18.96 | -11.35 | -18.37 | -6.41 | -14.61 | -9.07 | -11.79 | -16.43 | -4.70 |
| Net Income | -11.80 | -18.37 | -1.36 | -18.04 | -6.72 | -14.35 | -2.64 | -6.87 | -22.64 | -8.41 |
| Shares Outstanding | 6.71 | 3.24 | 0.83 | 0.68 | 0.17 | 0.10 | 0.02 | 0.01 | 0.01 | - |
| Earnings Per Share | -1.76 | -8.21 | -29.11 | -26.40 | -38.40 | -149.99 | -149.99 | -1,223.94 | -3,899.81 | -2,099.90 |
| Operating Cash Flow | -9.86 | -10.77 | -12.33 | -10.77 | -5.19 | -9.03 | -1.18 | -4.31 | -12.02 | -1.98 |
| Capital Expenditures | - | - | -0.45 | - | -0.04 | -0.05 | - | - | -0.12 | -0.01 |
| Free Cash Flow | -9.86 | -10.77 | -12.78 | -10.77 | -5.23 | -9.08 | -1.18 | -4.31 | -12.15 | -1.99 |
| Cash & Equivalents | 14.18 | 7.99 | 8.90 | 1.55 | 2.00 | 21.88 | 0.25 | 0.31 | 0.10 | 0.04 |
| Total Debt | 0.25 | - | 0.55 | 2.43 | 1.24 | - | 1.87 | 4.00 | 0.56 | 2.12 |
| Net Cash / Debt | 13.93 | 7.99 | 8.35 | -0.88 | 0.75 | 21.88 | -1.61 | -3.69 | -0.46 | -2.08 |
| Assets | 24.11 | 18.20 | 26.15 | 17.48 | 2.28 | 42.78 | 18.34 | 2.45 | 3.67 | 5.58 |
| Liabilities | 3.98 | 2.59 | 4.92 | 8.30 | 2.32 | 4.61 | 11.88 | 20.85 | 19.68 | 5.56 |
| Book Value | 20.13 | 15.61 | 21.23 | 9.18 | -0.04 | 38.17 | 6.46 | -18.39 | -16.03 | 0.02 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Diffusion Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
10 |
| CEO |
David G. Kalergis |
Stock Information
| Ticker Symbol |
DFFN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: DFFN |
Description
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.